XLRN - Acceleron Pharma Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 52.43B
Enterprise Value 32.03B
Trailing P/E N/A
Forward P/E 1-23.83
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)64.77
Price/Book (mrq)4.85
Enterprise Value/Revenue 354.07
Enterprise Value/EBITDA 6-16.23

Trading Information

Stock Price History

Beta (3Y Monthly) 0.85
52-Week Change 3-6.36%
S&P500 52-Week Change 3-0.33%
52 Week High 359.59
52 Week Low 337.01
50-Day Moving Average 342.71
200-Day Moving Average 342.58

Share Statistics

Avg Vol (3 month) 3308.67k
Avg Vol (10 day) 3240.75k
Shares Outstanding 545.77M
Float 45.38M
% Held by Insiders 114.01%
% Held by Institutions 187.23%
Shares Short (Jul 31, 2019) 43.99M
Short Ratio (Jul 31, 2019) 415.17
Short % of Float (Jul 31, 2019) 410.36%
Short % of Shares Outstanding (Jul 31, 2019) 47.54%
Shares Short (prior month Jun 28, 2019) 44.14M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-343.30%

Management Effectiveness

Return on Assets (ttm)-17.84%
Return on Equity (ttm)-28.72%

Income Statement

Revenue (ttm)37.52M
Revenue Per Share (ttm)0.76
Quarterly Revenue Growth (yoy)650.80%
Gross Profit (ttm)-17.16M
EBITDA -124.99M
Net Income Avi to Common (ttm)-119.63M
Diluted EPS (ttm)-2.44
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)430.76M
Total Cash Per Share (mrq)8.15
Total Debt (mrq)29.15M
Total Debt/Equity (mrq)5.83
Current Ratio (mrq)17.11
Book Value Per Share (mrq)9.48

Cash Flow Statement

Operating Cash Flow (ttm)-89.63M
Levered Free Cash Flow (ttm)-52.29M